RCKT
Rocket Pharmaceuticals, Inc. NASDAQ Listed Feb 18, 2015$3.35
+6.01%
vs $3.16
Mkt Cap $372.3M
52w Low $2.45
31.6% of range
52w High $5.30
50d MA $3.30
200d MA $3.54
P/E (TTM)
-1.7x
EV/EBITDA
—
P/B
1.3x
Debt/Equity
0.1x
ROE
-80.5%
P/FCF
-2.0x
RSI (14)
60.00
ATR (14)
$0.18
Beta
0.57
50d MA
$3.30
200d MA
$3.54
Avg Volume
2.8M
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
9 Cedarbrook Drive · Cranbury, NJ 08512 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.41 | -0.42 | -2.4% | 3.67 | +2.7% | -1.1% | -1.1% | +1.4% | -1.1% | -5.6% | — |
| Feb 26, 2026 | AMC | -0.42 | -0.38 | +9.5% | 4.53 | +1.3% | +10.6% | -0.8% | -3.4% | +0.4% | -3.7% | — |
| Nov 6, 2025 | AMC | -0.48 | -0.45 | +6.2% | 3.23 | +0.9% | -1.9% | -0.6% | +3.5% | +1.2% | -3.9% | — |
| Aug 7, 2025 | AMC | -0.57 | -0.59 | -3.5% | 3.09 | +1.0% | -7.4% | +2.1% | -0.3% | +6.2% | -1.9% | — |
| May 8, 2025 | AMC | -0.59 | -0.56 | +5.1% | 7.04 | -0.4% | -0.7% | +0.1% | -5.4% | -8.5% | +11.1% | — |
| Feb 27, 2025 | AMC | -0.68 | -0.62 | +8.8% | 9.40 | +1.6% | +0.5% | -7.0% | -1.5% | +6.4% | -2.4% | — |
| Nov 7, 2024 | AMC | -0.78 | -0.71 | +9.0% | 17.25 | +0.2% | +1.2% | -3.4% | -4.9% | -2.2% | -5.4% | — |
| Aug 5, 2024 | AMC | -0.74 | -0.74 | +0.0% | 19.96 | +4.5% | +0.9% | -6.1% | +1.2% | -0.5% | -0.5% | — |
| May 6, 2024 | AMC | -0.69 | -0.66 | +4.3% | 23.20 | +0.8% | +0.7% | -1.6% | +1.5% | -2.6% | +1.6% | — |
| Feb 26, 2024 | AMC | -0.80 | -0.64 | +20.0% | 29.79 | +5.0% | +3.2% | -5.6% | +0.9% | +4.2% | -6.0% | — |
| Nov 6, 2023 | AMC | -0.82 | -0.75 | +8.5% | 19.93 | +1.6% | +2.7% | -4.4% | -7.2% | +2.1% | +5.2% | — |
| Aug 10, 2023 | AMC | -0.80 | -0.82 | -2.5% | 16.78 | -1.2% | -1.5% | +1.2% | -2.8% | -2.8% | -2.9% | — |
| May 4, 2023 | AMC | -0.86 | -0.73 | +15.1% | 18.69 | +1.7% | +12.4% | +1.7% | -3.2% | +1.3% | -3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | BofA Securities | Maintains | Buy → Buy | — | $3.77 | $3.75 | -0.5% | -8.5% | +3.8% | +1.1% | -1.9% | -2.5% |
| Mar 27 | Chardan Capital | Maintains | Buy → Buy | — | $4.69 | $4.71 | +0.4% | -19.6% | -8.5% | +3.8% | +1.1% | -1.9% |
| Mar 2 | Goldman Sachs | Maintains | Sell → Sell | — | $5.01 | $4.95 | -1.2% | -0.8% | -3.4% | +0.4% | -3.7% | -5.0% |
| Feb 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.53 | $4.59 | +1.3% | +10.6% | -0.8% | -3.4% | +0.4% | -3.7% |
| Nov 18 | BofA Securities | Maintains | Buy → Buy | — | $3.04 | $2.90 | -4.6% | -3.3% | -2.0% | -1.4% | +3.2% | +3.4% |
| Nov 18 | JP Morgan | Downgrade | Overweight → Underweight | — | $3.04 | $2.90 | -4.6% | -3.3% | -2.0% | -1.4% | +3.2% | +3.4% |
| Oct 14 | Chardan Capital | Maintains | Buy → Buy | — | $3.47 | $3.92 | +13.0% | +23.1% | -0.7% | -5.7% | -7.2% | +7.8% |
| Oct 3 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $3.21 | $3.19 | -0.6% | -1.9% | +1.0% | -1.3% | +8.0% | +8.3% |
| Aug 20 | BofA Securities | Upgrade | Neutral → Buy | — | $2.91 | $3.83 | +31.6% | +28.9% | -0.5% | -2.4% | -2.7% | -4.2% |
| Aug 20 | Chardan Capital | Maintains | Buy → Buy | — | $2.91 | $3.83 | +31.6% | +28.9% | -0.5% | -2.4% | -2.7% | -4.2% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $2.86 | $2.90 | +1.4% | +2.1% | -0.3% | +6.2% | -1.9% | +0.7% |
| Aug 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.09 | $3.12 | +1.0% | -7.4% | +2.1% | -0.3% | +6.2% | -1.9% |
| Jul 25 | BofA Securities | Downgrade | Buy → Neutral | — | $3.21 | $3.11 | -3.1% | -2.2% | -1.0% | -3.2% | +4.3% | -2.9% |
| Jul 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.21 | $3.11 | -3.1% | -2.2% | -1.0% | -3.2% | +4.3% | -2.9% |
| Jul 24 | Needham | Maintains | Hold → Hold | — | $3.36 | $3.32 | -1.2% | -4.5% | -2.2% | -1.0% | -3.2% | +4.3% |
| Jul 24 | Chardan Capital | Maintains | Buy → Buy | — | $3.36 | $3.32 | -1.2% | -4.5% | -2.2% | -1.0% | -3.2% | +4.3% |
| Jun 17 | UBS | Maintains | Buy → Buy | — | $2.88 | $2.87 | -0.3% | -5.6% | +4.0% | -4.6% | -2.6% | +5.3% |
| Jun 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.77 | $2.76 | -0.4% | +6.9% | -1.4% | -5.1% | +10.8% | -1.6% |
| May 28 | BMO Capital | Maintains | Outperform → Outperform | — | $2.33 | $2.38 | +2.1% | +6.4% | +5.6% | -4.2% | +10.4% | +6.9% |
| May 28 | BofA Securities | Maintains | Buy → Buy | — | $2.33 | $2.38 | +2.1% | +6.4% | +5.6% | -4.2% | +10.4% | +6.9% |
| May 28 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $2.33 | $2.38 | +2.1% | +6.4% | +5.6% | -4.2% | +10.4% | +6.9% |
| May 28 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $2.33 | $2.38 | +2.1% | +6.4% | +5.6% | -4.2% | +10.4% | +6.9% |
| May 28 | JP Morgan | Downgrade | Overweight → Neutral | — | $2.33 | $2.38 | +2.1% | +6.4% | +5.6% | -4.2% | +10.4% | +6.9% |
| May 28 | Jefferies | Downgrade | Buy → Hold | — | $2.33 | $2.38 | +2.1% | +6.4% | +5.6% | -4.2% | +10.4% | +6.9% |
| May 28 | Chardan Capital | Maintains | Buy → Buy | — | $2.33 | $2.38 | +2.1% | +6.4% | +5.6% | -4.2% | +10.4% | +6.9% |
| May 27 | BofA Securities | Maintains | Buy → Buy | — | $6.27 | $2.30 | -63.3% | -62.8% | +6.4% | +5.6% | -4.2% | +10.4% |
| May 27 | Needham | Downgrade | Buy → Hold | — | $6.27 | $2.30 | -63.3% | -62.8% | +6.4% | +5.6% | -4.2% | +10.4% |
| May 16 | Wedbush | Maintains | Outperform → Outperform | — | $6.73 | $6.87 | +2.1% | -3.4% | -0.8% | +6.2% | -3.8% | -0.5% |
| May 16 | Chardan Capital | Maintains | Buy → Buy | — | $6.73 | $6.87 | +2.1% | -3.4% | -0.8% | +6.2% | -3.8% | -0.5% |
| May 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.73 | $6.87 | +2.1% | -3.4% | -0.8% | +6.2% | -3.8% | -0.5% |
| May 12 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $6.99 | $7.25 | +3.7% | +0.1% | -5.4% | -8.5% | +11.1% | -3.4% |
| May 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.99 | $7.25 | +3.7% | +0.1% | -5.4% | -8.5% | +11.1% | -3.4% |
| May 9 | JP Morgan | Maintains | Overweight → Overweight | — | $7.04 | $7.01 | -0.4% | -0.7% | +0.1% | -5.4% | -8.5% | +11.1% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $7.04 | $7.01 | -0.4% | -0.7% | +0.1% | -5.4% | -8.5% | +11.1% |
| May 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.04 | $7.01 | -0.4% | -0.7% | +0.1% | -5.4% | -8.5% | +11.1% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $4.79 | $4.61 | -3.8% | +12.7% | -8.5% | +6.7% | +12.1% | +10.5% |
| Mar 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.45 | $9.42 | -0.3% | -7.0% | -1.5% | +6.4% | -2.4% | -2.4% |
| Mar 3 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $9.45 | $9.42 | -0.3% | -7.0% | -1.5% | +6.4% | -2.4% | -2.4% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $9.45 | $9.42 | -0.3% | -7.0% | -1.5% | +6.4% | -2.4% | -2.4% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $9.40 | $9.55 | +1.6% | +0.5% | -7.0% | -1.5% | +6.4% | -2.4% |
| Feb 28 | Chardan Capital | Maintains | Buy → Buy | — | $9.40 | $9.55 | +1.6% | +0.5% | -7.0% | -1.5% | +6.4% | -2.4% |
| Feb 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.40 | $9.55 | +1.6% | +0.5% | -7.0% | -1.5% | +6.4% | -2.4% |
| Nov 19 | Needham | Maintains | Buy → Buy | — | $13.66 | $13.81 | +1.1% | -3.7% | -0.9% | -1.9% | +10.3% | -0.1% |
| Nov 19 | Leerink Partners | Maintains | Outperform → Outperform | — | $13.66 | $13.81 | +1.1% | -3.7% | -0.9% | -1.9% | +10.3% | -0.1% |
| Nov 19 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.66 | $13.81 | +1.1% | -3.7% | -0.9% | -1.9% | +10.3% | -0.1% |
| Nov 19 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.66 | $13.81 | +1.1% | -3.7% | -0.9% | -1.9% | +10.3% | -0.1% |
| Nov 18 | Chardan Capital | Maintains | Buy → Buy | — | $13.98 | $14.10 | +0.9% | -2.3% | -3.7% | -0.9% | -1.9% | +10.3% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $17.45 | $17.65 | +1.1% | -3.4% | -4.9% | -2.2% | -5.4% | -5.7% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $17.25 | $17.29 | +0.2% | +1.2% | -3.4% | -4.9% | -2.2% | -5.4% |
| Sep 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $18.46 | $18.22 | -1.3% | +0.1% | -7.3% | -0.9% | -5.3% | +2.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 | Shah Gaurav | CEO | Sell | 55,684 | $3.09 | $172K | 1,061,724 | -0.33% | -4.30% |
| May 19, 2026 | Militello John | See Remarks | Sell | 384 | $3.01 | $1K | 89,780 | -4.82% | +1.66% |
| May 19, 2026 | Shah Gaurav | CEO | Sell | 2,409 | $3.01 | $7K | 1,040,918 | -4.82% | +1.66% |
| May 19, 2026 | Wilson Martin | General Counsel | Sell | 662 | $3.01 | $2K | 677,977 | -4.82% | +1.66% |
| May 13, 2026 | Militello John | See Remarks | Sell | 855 | $3.61 | $3K | 90,164 | -4.41% | +4.71% |
| May 13, 2026 | Shah Gaurav | CEO | Sell | 2,728 | $3.61 | $10K | 1,043,327 | -4.41% | +4.71% |
| May 13, 2026 | Wilson Martin | General Counsel | Sell | 3,361 | $3.61 | $12K | 678,639 | -4.41% | +4.71% |
| May 7, 2026 | Chaudhuri Sarbani | See Remarks | Sell | 17,650 | $3.84 | $68K | 267,510 | +1.39% | -5.54% |
8-K · 2.01
!!! Very High
Rocket Pharmaceuticals, Inc. -- 8-K 2.01: Acquisition Completed
Jun 12
8-K
Rocket Pharmaceuticals, Inc. -- 8-K Filing
I cannot provide a meaningful analysis based on this filing summary, as it appears to contain only technical metadata and XBRL reference information rather than substantive business information about Rocket Pharmaceuticals.
May 21
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Rocket Pharmaceuticals disclosed material information via press release, likely regarding clinical trial results or pipeline updates that could significantly impact stock valuation and investor expectations for the biotech company's future performance.
Mar 27
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
Rocket (RCKT) agreed to issue equity to Cantor Fitzgerald, likely diluting existing shareholders but providing capital for growth or debt reduction.
Mar 10
8-K
Rocket Pharmaceuticals, Inc. -- 8-K Filing
Rocket Pharmaceuticals reported 2025 results highlighting progress in its genetic therapy pipeline, particularly in cardiovascular applications with ongoing Danon disease experience and advancement in two additional cardiomyopathy programs.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 17,687,772 | $63M | — | Mar 2026 |
| 2 | Morgan Stanley | 7,882,754 | $28M | Added | Dec 2025 |
| 3 | Citigroup Inc | 5,246,349 | $18M | Added | Dec 2025 |
| 4 | Vanguard Portfolio Management Llc | 4,690,215 | $17M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 3,775,736 | $14M | New | Mar 2026 |
| 6 | Maverick Capital Ltd | 3,567,372 | $13M | Added | Mar 2026 |
| 7 | Nuveen, Llc | 3,128,753 | $11M | Added | Mar 2026 |
| 8 | Millennium Management | 3,118,124 | $11M | Added | Mar 2026 |
| 9 | Aqr Capital Management Llc | 3,069,930 | $11M | Added | Mar 2026 |
| 10 | Marshall Wace, Llp | 3,038,715 | $11M | Added | Mar 2026 |
| 11 | Monaco Asset Management Sam | 2,987,296 | $10M | Added | Dec 2025 |
| 12 | D.e. Shaw & Co | 2,169,625 | $8M | Reduced | Mar 2026 |
| 13 | Ubs Group Ag | 1,298,173 | $5M | Added | Mar 2026 |
| 14 | Two Sigma Investments, Lp | 1,097,623 | $4M | Reduced | Mar 2026 |
| 15 | Point72 Asset Management | 1,012,126 | $4M | Added | Mar 2026 |
| 16 | Opaleye Management Inc. | 955,000 | $3M | New | Dec 2025 |
| 17 | Jpmorgan Chase & Co | 796,224 | $3M | Reduced | Mar 2026 |
| 18 | Aberdeen Group Plc | 664,821 | $2M | New | Mar 2026 |
| 19 | Woodline Partners Lp | 641,222 | $2M | New | Mar 2026 |
| 20 | Northern Trust Corp | 640,840 | $2M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$372.3M
Enterprise Value
$183.3M
P/E (TTM)
-1.67x
Forward P/E
—
PEG Ratio
0.07x
P/B
1.34x
P/S
—
P/FCF
-1.95x
EV/EBITDA
—
Shares Out
111.1M
Financials (TTM)
Revenue
$0
Net Income
-$223.1M
EBITDA
-$210.2M
Free Cash Flow
-$190.5M
Op Cash Flow
-$190.0M
EPS Basic
$-2.01
EPS Diluted
$-2.01
EPS Forward
$-1.15
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$330.4M
Total Liab.
$53.2M
Total Equity
$277.2M
Cash
$188.9M
LT Debt
$0
Book Value/Sh
$2.49
Debt/Equity
0.09x
Current Ratio
6.38
Quick Ratio
6.38
Returns & Growth
ROE
-80.5%
ROA
-67.5%
ROIC
-75.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
+26.4%
Price Returns
2W
-9.7%
1M
-11.8%
3M
-38.7%
6M
-10.2%
12M
+22.3%
Technicals
52W High
$5.30
52W Low
$2.45
50d MA
$3.30
200d MA
$3.54
RSI (14)
60.00
ATR (14)
$0.18
Beta
0.57
Avg Volume
2.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.00
High
$5.00
Low
$5.00
Median
$5.00
Data updated apr 26, 2026 10:04pm
· Source: financialmodelingprep.com